BioNTech has decided to produce two billion doses of its experimental coronavirus vaccine in 2021, company said in a statement."In order to respond to an increased global demand, we plan to manufacture two billion doses of our COVID-19 vaccine in 2021 by expanding the previously expected output of 1.3 billion doses by more than 50 per cent," the German biotechnology firm said. "We are on track to scale-up our manufacturing capacities," the statement said.BioNTech has partnered with US pharma giant Pfizer Inc to develop a mRNA vaccine against novel coronavirus.
Dubbed as BNT162b, the COVID-19 vaccine shot relies on messenger RNA technology. Using mRNA, which essentially teaches the body’s cells to become vaccine factories, allowed it to be.